Orexo prices DTx at $600 to $1,000. Pear: $1,000 to $1,600.

Issue 045.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan. 9680e452-e6b2-4094-9dd7-2c2081fa1deb.png

Welcome to E&O.

Last week's newsletter had a 54 percent open rate. Here's what's happening this week:

We are coming to the end of week two in self-isolation up here in the Greater Boston Area. Here's hoping all of you are staying safe and feeling healthy. Onward.
If you have plans to launch a digital health product in France, the Dutch government commissioned an in-depth analysis of all things "e-health" in that country. Perhaps coincidentally, Health Advances has a (shorter but still in-depth) look at digital health in France this month, too -- read it here.
Last week I mentioned the FDA's move to allow medical device makers to tweak their clearances for remote monitoring devices in order to use them in the fight against COVID--19. Alivecor was among the digital

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Orexo prices DTx at $600 to $1,000. Pear: $1,000 to $1,600.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.